Article Text

Download PDFPDF

1423 Novel immunotherapy based on commensal-derived peptides to drive an effective CD8 T Cell response against selected tumor-associated antigens (TAAs)
  1. Alice Talpin1,
  2. Jerome Kervevan2,
  3. Lucie Aubergeon2,
  4. Ana Maia3,
  5. Tifanny Mersceman Blanc2,
  6. Diana Bachrouche2,
  7. Chloé Ventujol2,
  8. Léa Bernard2,
  9. Amandine Manteau2,
  10. Cecile Gouttefangeas3,
  11. Jose Villasboas4,
  12. Antonello Pinto5,
  13. Francesc Bosch6,
  14. Ramon García-Sanz7,
  15. Carlos Grande Garcia8,
  16. Stephen D Smith9,
  17. Luca Arcaini10,
  18. Reid Merryman11,
  19. Jonathan W Friedberg12,
  20. Stephen Ansell4,
  21. Philippe Armand11,
  22. Pier Zinzani13,
  23. Christophe Bonny2,
  24. Laurent Chene2 and
  25. Joao Gamelas Magalhaes2
  1. 1Enterome, Evry, France
  2. 2Enterome, Paris, France
  3. 3University of Tübingen, Tübingen, Germany
  4. 4Mayo Clinic Cancer Center, Rochester, MN, USA
  5. 5Fondazione G. Pascale, Naples, Italy
  6. 6University Hospital Vall d’Hebron, Barcelona, Spain
  7. 7Hospital Universitario de Salamanca, Salamanca, Spain
  8. 8Universidad de Navarra, Pamplona, Spain
  9. 9Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  10. 10IRCCS Fondazione San Matteo, Pavia, Italy
  11. 11Dana-Farber Cancer Institute, Boston, MA, USA
  12. 12University of Rochester, Rochester, NY, USA
  13. 13University of Bologna, Bologna, Italy
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Efficacy demonstration of a unique peptide-based immunotherapy as potent approach for cancer treatment. This strategy relies on the activation of commensal-specific T cells which cross-react against peptides derived from Tumor-Associated Antigens (TAAps) found in various solid tumors, including glioblastoma, adrenocortical carcinoma and colorectal cancer. The same strategy is also used to target lineage-specific markers in hematologic cancers such as B cell malignancies.

Methods The gut microbiota has the outstanding ability of regulating the human immune system through commensal antigens. Since specific microbiota peptides exhibit significant homology with particular TAAs, the full potential of cross-reactive CD8+ T cells that recognize both commensal peptides and poorly immunogenic tumor antigens can thus be harnessed against tumor cells.

We identified a specific set of commensal derived peptides, referred to as OncoMimics™ (OMP) peptides, which elicit cross-reactive cytotoxic CD8+ T cell responses against TAAps owing to their strong sequence homology. The capacity of these OMPs to induce TAAps-specific cross-reactive CD8+ T cell responses in humans is evaluated through peptide-MHC multimer staining and flow cytometry-based cytotoxic assays.

Results Experiments conducted on human peripheral blood mononuclear cells (PBMCs) demonstrate that OMPs can be recognized by CD8 T cells in a significant proportion of healthy individuals. Upon in vitro stimulation, OMPs induce the expansion of CD8+ T cells that recognize homologous peptides derived from tumor antigen targets. Importantly, these T cells display cytotoxic capabilities against tumor cells presenting the corresponding TAAps on their surface.

Further support for this approach comes from ongoing clinical trials, since we displayed that CD8+ T cells from indolent Non-Hodgkin Lymphoma (iNHL) patients treated with EO2463 immunotherapy (SIDNEY, EONHL1–20 phase 1/2 trial) are cytotoxic against TAA protein-expressing tumor cell lines.1

Conclusions These data provide compelling evidence that OncoMimic peptides sharing a high degree of homology with TAAps can be utilized to generate an effective anti-tumor immune response.



Ethics Approval Buffy coats from healthy donors were provided from the Blood Bank (Etablissement français du sang (EFS)) of Rungis. This study was performed according to established ethical guidelines, and all blood donors gave informed consent. Patient cells are coming from the ongoing EONHL1–20 phase 1/2 trial.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.